KUKU

KU ScholarWorks

  • myKU
  • Email
  • Enroll & Pay
  • KU Directory
    • Login
    View Item 
    •   KU ScholarWorks
    • Dissertations and Theses
    • Theses
    • View Item
    •   KU ScholarWorks
    • Dissertations and Theses
    • Theses
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Modified-Release Formulations for Cancer Therapy

    Thumbnail
    View/Open
    Abdelaziz_ku_0099M_18241_DATA_1.pdf (4.568Mb)
    Issue Date
    2022-05-31
    Author
    Abdelaziz, Moustafa
    Publisher
    University of Kansas
    Format
    160 pages
    Type
    Thesis
    Degree Level
    M.S.
    Discipline
    Bioengineering
    Rights
    Copyright held by the author.
    Metadata
    Show full item record
    Abstract
    Cancer is one of the most virulent diseases in modern times that is ranked as the secondleading cause of death worldwide. The conventional and modern treatment protocols (e.g. chemotherapy and immunotherapy) for cancer still have some drawbacks that range from mild adverse effects to limited efficacy and the risk of tumor recurrence. Long-acting depots can mitigate these drawbacks and lend the current therapeutic protocols with improved efficacy and safety through their numerous advantages such as localizing the drug administration, prolonging the drug exposure, protecting the drug against degradation, conferring targeting functionality, and reducing side effects. Therefore, the utilization of long-acting depots for cancer therapy was investigated in this thesis. The first chapter describes the long-acting depots concerning their definition, historical development, advantages, and the major classes that are prevalent in the pharmaceutical market. The second and third chapters present the utilization of long-acting depots for cancer immunotherapy. The second chapter discusses the development of multivesicular liposomes (MVLs) for the localized depot delivery of ingenol-3-angelate (I3A), a protein kinase C agonist. The in vitro release study, in vitro cytotoxicity assay, and the in vivo pharmacokinetics demonstrated the potential MVLs to overcome I3A’s poor solubility, sustain drug release, and prevent the rapid clearance from the injection site. The third chapter describes the use of the ethyl oleate (EO) oil vehicle for prolonging the release of two developed kifunensine (KIF), named JDW-II-002 and JDW-II-008. These analogues act as potent inhibitors of type I mannosidase and potential agents for cancer immunotherapy. The therapeutic efficiency of the developed formulation was examined using an immunocompetent mice model of colon cancer which showed a delay in the tumor growth with JDW-II-008 treatments. The immunohistochemistry analysis demonstrated overexpression of high mannose N-glycans with all KIF treatments and an indication2 of a possible antitumor immune response. While chapter four discusses a photodynamic therapy (PDT) approach for the treatment of head and neck squamous cell carcinoma (HNSCC). In that chapter, we relied on an alternative approach to long-acting depots, in which we developed hyaluronan nanoconjugates to enhance the specific tumor cells’ uptake and retention of the photosensitizer, pyropheophorbide-a (PPa). The results demonstrated improvement in the water solubility of PPa, increase in its accumulation in HNSCC, and preservation of its photoactivity. The in vivo efficacy and survival time of the developed formulation were statistically better than conventional PDT therapy. Accordingly, we believe in the long-acting depots’ potential to substantially contribute to the pursuit of next-generation cancer therapeutics.
    URI
    https://hdl.handle.net/1808/34105
    Collections
    • Theses [3901]

    Items in KU ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.


    We want to hear from you! Please share your stories about how Open Access to this item benefits YOU.


    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    Browse

    All of KU ScholarWorksCommunities & CollectionsThis Collection

    My Account

    Login

    Statistics

    View Usage Statistics

    Contact KU ScholarWorks
    785-864-8983
    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    785-864-8983

    KU Libraries
    1425 Jayhawk Blvd
    Lawrence, KS 66045
    Image Credits
     

     

    The University of Kansas
      Contact KU ScholarWorks
    Lawrence, KS | Maps
     
    • Academics
    • Admission
    • Alumni
    • Athletics
    • Campuses
    • Giving
    • Jobs

    The University of Kansas prohibits discrimination on the basis of race, color, ethnicity, religion, sex, national origin, age, ancestry, disability, status as a veteran, sexual orientation, marital status, parental status, gender identity, gender expression and genetic information in the University’s programs and activities. The following person has been designated to handle inquiries regarding the non-discrimination policies: Director of the Office of Institutional Opportunity and Access, IOA@ku.edu, 1246 W. Campus Road, Room 153A, Lawrence, KS, 66045, (785)864-6414, 711 TTY.

     Contact KU
    Lawrence, KS | Maps